Search Results

Relmada Therapeutics, Inc. today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat on Thursday, June 6, 2024, at 7:30am ET at the 2024 Jefferies Global Healthcare Conference in New York, NY.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024, at 11:20am ET.

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2024.

Relmada Therapeutics, Inc. today announced that they will participate in the Leerink Partners Global Biopharma Conference.

Relmada Therapeutics, Inc. announced that it will report its financial results for the first quarter ended March 31, 2024 after the market close on Wednesday, May 8, 2024.

Relmada Therapeutics, Inc. today provided a corporate update, highlighted the Company’s key 2023 accomplishments and outlined its anticipated 2024 clinical development milestones.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023.